Economic burden of hospital-requiring infections and venous thromboembolism in the last year of life in advanced breast cancer: a complication-specific cost analysis
Year: 2026
Type: article
Study design: Observational Study
Abstract: BACKGROUND AND PURPOSE: End-of-life healthcare costs in advanced breast cancer (ABC) are substantial, yet the contribution of acute, life-threatening complications, hospital-requiring infections and venous thromboembolism (VTE), remains uncharacterised. We quantified adjusted complication-specific costs. Patient/material and methods: Population-based cohort study of 1,363 women who died with ABC in the Stockholm Region (2015-2023). Healthcare costs during the last 12 months of life were estimated using the Region Stockholm simulated cost (SIM) model and stratified by complication status, age group, and Hospital Frailty Risk Score (HFRS). Generalised linear models estimated the independent associations between hospital-requiring infections, VTE and total costs, adjusting sequentially for age, frailty risk, and systemic therapy. RESULTS: Overall mean costs were 597 thousand SEK (tSEK; 95% CI: 578-616). Hospital-requiring infections occurred in 18% of patients and were independently associated with 29% higher costs after full adjustment (cost ratio 1.29, 95% confidence interval [CI]: 1.20-1.39). VTE occurred in 8% of patients, of whom 80% had pulmonary embolism; it was associated with higher costs unadjusted (1.16, p = 0.010) but not after adjustment for frailty risk (1.08, 95% CI: 0.97-1.21). Concomitant VTE (27 patients, 11% of those infected) gave costs similar to infection alone. High frailty risk showed the strongest independent association with cost in the infection model (cost ratio 1.54, 95% CI: 1.34-1.78). INTERPRETATION: Hospital-requiring infections were independently associated with higher end-of-life costs in ABC; VTE was not, once frailty risk was adjusted for. These findings add a complication-specific dimension to frailty-based risk stratification and support targeted prevention in end-of-life care.
Source: Acta Oncologica
Institutions: Linköping University, Karolinska Institutet
Language: English
Subfield: Economics and Econometrics
Domain: Social Sciences
Open Access status: diamond
OpenAlex ID: W7236337774
